Key result
In adults with primary mitochondrial myopathy, the highest dose of elamipretide increased 6-minute walk distance by a mean of 64.5 m compared to 20.4 m with placebo after 5 days (p=0.053).
Why the study?
Does intravenous elamipretide improve distance walked in the 6-minute walk test in adults with primary mitochondrial myopathy?
RCT (n=36)
double-blind
randomized
Yes
Does intravenous elamipretide improve distance walked in the 6-minute walk test in adults with primary mitochondrial myopathy?
Absolute Event Rate: 64.5% vs 20.4%
p-value: p=0.053
Elamipretide improves short-term exercise performance in adults with primary mitochondrial myopathy without significant safety concerns.
No takes yet. Share an insight, caveat, or question.
Supports short-term elamipretide use to improve exercise capacity in primary mitochondrial myopathy; provides first RCT confirmation of benefit.
Karaa et al. (2018) conducted an RCT in primary mitochondrial myopathy (n=36). elamipretide vs. placebo was evaluated on change in distance walked in the 6-minute walk test (6MWT) after 5 days of treatment (p=0.053). In adults with primary mitochondrial myopathy, the highest dose of elamipretide increased 6-minute walk distance by a mean of 64.5 m compared to 20.4 m with placebo after 5 days (p=0.053).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: